Coronavirus Disease 2019 (COVID-19) Situation Report

Data as reported by national authorities by 24:00 local time 21 February 2021

Situation Report No. 236 - Kingdom of Bahrain

22th of February, 2021



	Glo	obal	Eastern Mediterranean Region		
	COVID-19 Cases	COVID-19 Deaths	COVID-19 Cases	COVID-19 Deaths	
Total	110,749,023	2,455,131	6,181,023	141,915	
New	359,488	9,075	25,479	318	

Kingdom of Bahrain

	Confirmed Cases	Recovered Cases	Deaths	Active Cases	Critical Cases	PCR Tests
Total	117,809	110,007	423	7,379	71	2,994,188
New	575	922	3	-	-	13,436

126,000


116,000 106.000 96,000 113.590

HIGHLIGHTS

- The mortality were: 3 Male Bahraini citizens (59, 81, and 83 years old).
 Increasing number of iditizens and residents continue to take COVID-19 vacine in Bahrain; and Ministry of Health (MOH) revealed that
 total number of individuals vaccinated as of 21 February 2021 is 274,960.
 The National Institution for Human Rights (NIRR) confirmed that all precautionary measures have been carried out to protect health and
- safety of immates in Bahrain during the pandemic. Assistant Chief of Public Security called on the public to comply with the precautionary measures against COVID-19. Nationwide inspections intersified to identify COVID-19 protocols violators, warning of new Coronavirus strains spreading rapidly

- Nationwide inspections intensified to identify COVID-19 protocols violators, warning of new Coronavirus strains spreading rapidly
 among younger people.
 WHO: Responding to non-communicable diseases during and beyond the COVID-19 pandemic; see link below.
 WHO: Interim guidance on Antigen-detection in the diagnosis of SARS-CoV-2 infection using rapidlymmun oassay; see link below.
 WHO: Interim guidance on Antigen-detection in the diagnosis of SARS-CoV-2 infection using rapidlymmun oassay; see link below.
 WHO: SAGE values framework for the allocation and prioritization of COVID-19 vaccination; see link below.
 WHO: SAGE values framework for the allocation and prioritization of COVID-19 vaccinating rubbilic health crises; see link below.
 WHO: CoVID-19 vaccine introduction and deployment costing tool; see link below.
 WHO: COVID-19 vaccine introduction and deployment costing tool; see link below.
 WHO: CovID-19 vaccine introduction and deployment costing tool; see link below.
 WHO: CovID-19 vaccine introduction and deployment costing tool; see link below.
 WHO: CovID-19 vaccine introduction and periorition for COVID-19 vaccinations for current and future COVID-19 place bocontrolled vaccine trials and trial unbilinding; see link below.
 WHO: Risk assessment tool to Inform mitigation measures for international travel in the context of COVID-19: see link below.
 WHO: Risk assessment tool to Inform mitigation measures for international travel in the context of COVID-19: see link below.

- Controllere vacche trad and trad unominionity see inite below. WHO: Risk assessment tool to inform mitigation measures for international travel in the context of COVID-19; see link below. WHO: Sixes its first emergency use validation for a COVID-19 vaccine and emphasizes need for equitable global access; see link below. WHO: Genomic sequencing of SARS-COV-2: a guide to implementation for maximum impact on public health; see link below. WHO: Interim recommendations for use of the Pfizer-BioNTech COVID-19 vaccine, BNT162b2, under Emergency Use Listing; see link
- WHO: Mount in the second second
- WHO: Analysing and using routine data to monitor the effects of COVID-19 on essential health services: practical guide for national subnational decision-makers; see link below.
 WHO: Background document on mRN4 vaccine BNT162b2 (Pfizer-BioNTech) against COVID-19; see link below.
 WHO: Scientists tackle vaccine safety, efficacy and access at global R&D forum; see link below.
 WHO: Contine global consultation on contact tracing for COVID-19, 911 une 2020; see link below.
 WHO: Online global consultation on contact tracing for COVID-19, 911 une 2020; see link below.
 WHO: Contact tracing in the context of COVID-19; see link below.
 WHO: Contact tracing in the context of COVID-19; see link below.
 WHO: Background document on the mRNA-1273 vaccine (Moderna) against COVID-19; see link below.
 WHO: Contact tracing in the context of ForUND-19; see link below.
 WHO: Contact tracing in the context of COVID-19; see link below.
 WHO: Background document on the mRNA-1273 vaccine (Moderna) against COVID-19; see link below.
 WHO: Weekly operational update on COVID-19: -13 February 2021; see link below.
 WHO: With Cortol-19: Occupational health and afterly for health workers; see link below.
 WHO: Sits two additional COVID-19: -13 February 2021; see link below.
 WHO: Sits two additional COVID-19: vaccines for emergency use and COVAX roll-out; see link below.
 WHO: Sits two additional COVID-19: vaccines global equitable access to tests, treatments and vaccines in 2021; see link below.
 WHO: Site two additional COVID-19: see link below.
 WHO: Site two additional COVID-19: vaccines for emergency use and COVAX roll-out; see link below.
 WHO: Site two additional COVID-19: see link below.
 WHO: Site two additional COVID: 19: see link below.




IMPORTANT LINKS

	dates on MOH website:
https://www.moh.go	w.bh/
 WHO's COVID-19 v 	weekly situation reports:
	t/docs/default-source/coronaviruse/situation-reports/20200817-weekly-epi-update 1.pdf?sfvrsn=b6d49a76_4 Dashboard: https://covid19.who.int/
WHO: New research	ch helps to increase understanding of the impact of COVID19 for pregnant women and their babies:
	t/news-room/detail/01-09-2020-new-research-helps-to-increase-understanding-of-the-impact-of-covid-19-for-pregnant-women-and-their-babies
	to non-communicable diseases during and beyond the COVID-19 pandemic : https://bit.ly/2Svds0r Global Supply Chain System(COVID-19) catalogue:
	/publications///item/emergency-global-supply-chain-system-(covid-19)-catalogue
	o pointaining in tempering genergeous as pay in their space form a spectra form and the spect
	ince on Anogen-detection in the diagnosis of SKRS-COVE intection using rapidimining dasags .utc.y/210jVP framework for the allocation and prioritization of COVID-19 vaccination .util.y/210jVPV
	namework to the anotation and promotion or COVID-19 resurrences or similar public health crises: https://www.who.int/publications//item/978924001746
COVID-19 vaccine i	ntroduction and deployment costing tool: https://www.who.int/publications//item/10665337553
	Jse Designation of COVID-19 candidate vaccines: Ethical considerations for current and future COVID-19 placebo-controlled vaccine trials and trial unblinding:
https://www.who.in	t/publications/l/item/WHO-2019-nCoV-Policy_Brief-EUD_placebo-controlled_vaccine_trials-2020.1
 WHO: Risk assessm 	ent tool to inform mitigation measures for international travel in the context of COVID-19:
https://www.who.in	t/publications///item/WHO-2019-nCoV-Risk-based_international_travel-Assessment_tool-2020.1
 WHO issues its first 	t emergency use validation for a COVID-19 vaccine and emphasizes need for equitable global access:
https://www.who.in	t/news/item/31-12-2020-who-issues-its-first-emergency-use-validation-for-a-covid-19-vaccine-and-emphasizes-need-for-equitable-global-access
• WHO: Genomic sec	quencing of SARS-CoV-2: a guide to implementation for maximum impact on public health:
https://www.who.in	t/publications//item/9789240018440
	mmendations for use of the Pfizer–BioNTech COVID-19 vaccine, BNT162b2, under Emergency Use Listing:
	t/publications/i/item/WHO-2019-nCoV-vaccines-SAGE_recommendation-BNT162b2-2021.1
	tists double down on SARS-CoV-2 variants research at WHO-hosted forum:
	t/news/item/12-01-2021-global-scientists-double-down-on-sars-cov-2-variants-research-at-who-hosted-forum
	nd using routine data to monitor the effects of COVID-19 on essential health services: practical guide for national and subnational decision-makers:
	<pre>k/publications/i/item/WHO-2019-nCoV-essential_health_services-monitoring-2021.1</pre>
	document on mRNA vaccine BNT162b2 (Pfizer-BioNTech) against COVID-19:
	<pre>t/publications/i/item/background-document-on-mma-vaccine-bnt162b2-(pfizer-biontech)-against-covid-19</pre>
	ckle vaccine safety, efficacy and access at global R&D forum:
	t/news/item/16-01-2021-scientists-tackle-vaccine-safety-efficacy-and-access-at-global-r-d-forum
	Committee on COVID-19 advises on variants, vaccines:
	t/news/item/15-01-2021-emergency-committee-on-covid-19-advises-on-variants-vaccines
	al consultation on contact tracing for COVID-19, 9-11 June 2020:
	t/publications///item/online-global-consultation-on-contact-tracing-for-covid-19-9-11-june-2020 irtual Press conference transcript - 1 February 2021:
	(cal ress concerne danschpt - 1 redram 2021) (/cablications/m/tem/covid-19-virtual-press-conference-transcript1-february-2021
	<pre>cypubications/myitem/covid=19-wrtual-press-conterence-transcripti-tebruary-zuzz; ing in the context of COVID-19: https://www.who.int/publications//item/contact+tracing-in-the-context-of-covid-19</pre>
• WHO: Background	document on the mRNA-1273 vaccine (Moderna) against COVID-19:
	t/publications//item/background-document-on-the-mrna-1273-vaccine-(moderna)-against-covid-19
 WHO: COVID-19-0 	Occupational health and safety for health workers: https://www.who.int/publications/i/item/WHO-2019-nCoV-HCW_advice-2021.1
	rational update on COVID-19 - 13 February 2021: https://www.who.int/publications/m/item/weekly-operational-update-on-covid-1913-february-2021
	itional COVID-19 vaccines for emergency use and COVAX roll-out:
	t/news/item/15-02-2021-who-lists-two-additional-covid-19-vaccines-for-emergency-use-and-covax-roll-out
	ommit US\$ 4.3 billion to finance global equitable access to tests, treatments and vaccines in 2021:
	t/news/item/19-02-2021-g7-leaders-commit-us-4.3-billion-to-finance-global-equitable-access-to-tests-treatments-and-vaccines-in-2021
	eral's statement on Tanzania and COVID-19:
https://www.who.in	t/news/item/20-02-2021-who-director-general-s-statement-on-tanzania-and-covid-19




Total Number of Cases

114,361 115,057 115,705 116,482 117,234 117,809







IMPORTANT CONTACTS

• The National Focal Person is Dr. Najat Mohamed Abulfateh, email: NAli5@health.gov.bh

• International Health Regulations focal person is Dr. Kubra Salman, email: knasser@health.gov.bh